Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial

Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial

ABSTRACT Aims/Introduction Clinical evidence is lacking about the influence of sodium–glucose cotransporter 2 inhibitors on white blood cell (WBC) counts, a commonly used and widely available marker of inflammation. The aim of the present analysis was to assess the effect of canagliflozin relative t...

Full description

Bibliographic Details
Main Authors:	Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Ikuko Nakamura, Kazuo Matsunaga, Yukio Ozaki, Tohru Minamino, Masataka Sata, Koichi Node, CANDLE trial investigators
Format:	Article
Language:	English
Published:	Wiley 2022-12-01
Series:	Journal of Diabetes Investigation
Subjects:	Chronic heart failure Sodium–glucose cotransporter 2 inhibitor White blood cell
Online Access:	https://doi.org/10.1111/jdi.13899

Similar Items

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
by: Akira Sezai, et al.
Published: (2022-07-01)

Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
by: Atsushi Tanaka, et al.
Published: (2022-08-01)

Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
by: Shinji Kishimoto, et al.
Published: (2023-05-01)

EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
by: Rishad Ahmed, et al.
Published: (2017-01-01)

Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
by: Shuqin Du, et al.
Published: (2022-10-01)

Proteomic Profiling of SGLT-2 Inhibitor Canagliflozin in a Swine Model of Chronic Myocardial Ischemia
by: Dwight D. Harris, et al.
Published: (2024-03-01)

Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia
by: Sharif A. Sabe, et al.
Published: (2023-01-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following <i>In Vitro</i> Vascular Ischemia/Reperfusion Injury in Rats
by: Sevil Korkmaz-Icöz, et al.
Published: (2021-07-01)

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
by: K M Prasanna Kumar, et al.
Published: (2017-01-01)

Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
by: Xue Yang, et al.
Published: (2023-10-01)

Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study
by: Sammar Fathy Elhabal, et al.
Published: (2023-12-01)

Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation
by: Luxun Tang, et al.
Published: (2023-12-01)

The role of SLC12A family of cation-chloride cotransporters and drug discovery methodologies
by: Shiyao Zhang, et al.
Published: (2023-12-01)

K+/Cl− cotransporter 2 (KCC2) and Na+/HCO3− cotransporter 1 (NBCe1) interaction modulates profile of KCC2 phosphorylation
by: Abhishek Pethe, et al.
Published: (2023-10-01)

Lighting the candle for quality improvement: the CANDLE programme
by: L. Fletcher, et al.
Published: (2023-06-01)

Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
by: Dae Jung Kim, et al.
Published: (2023-03-01)

Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
by: Atsushi Tanaka, et al.
Published: (2023-07-01)

The Flame of the Candle
by: Valentine Ackland
Published: (2020-03-01)

Experimental and numerical investigations of biochar-facilitated Cd2+ transport in saturated porous media: role of solution pH and ionic strength
by: Dan Zhou, et al.
Published: (2023-03-01)

Subanalysis of the AUGUSTUS trial
by: T. V. Pavlova, et al.
Published: (2020-09-01)

Candle for a corpse /
by: 532290 Granger, Ann
Published: (1995)

The moon is a candle /
by: Siti Zainon Ismail, 1949-, author, et al.
Published: (1992)

Lighting a candle
by: Peter McCulloch, et al.
Published: (2019-08-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Optogenetic ion pumps differ with respect to the secondary pattern of K+ redistribution
by: R. Ryley Parrish, et al.
Published: (2023-08-01)

Structural Pharmacology of Cation-Chloride Cotransporters
by: Yongxiang Zhao, et al.
Published: (2022-11-01)

Protective Role of IRBIT on Sodium Bicarbonate Cotransporter-n1 for Migratory Cancer Cells
by: Soyoung Hwang, et al.
Published: (2020-08-01)

Light a penny candle /
by: 421195 Binchy, Maeve
Published: (c198)

Simple methods of candle manufacture/
Published: (1978)

The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials
by: Feifei Zhou, et al.
Published: (2022-09-01)

Ptpn20 deletion in H-Tx rats enhances phosphorylation of the NKCC1 cotransporter in the choroid plexus: an evidence of genetic risk for hydrocephalus in an experimental study
by: Hanbing Xu, et al.
Published: (2022-06-01)

Easily Attach/Detach Reattachable EEG Headset with Candle-like Microneedle Electrodes
by: Takumi Kawana, et al.
Published: (2023-02-01)

SGLT2 Inhibitors as Potential Anticancer Agents
by: Debasish Basak, et al.
Published: (2023-06-01)

Glucose Transporters as a Target for Anticancer Therapy
by: Monika Pliszka, et al.
Published: (2021-08-01)

Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
by: Takeshi Horii, et al.
Published: (2023-11-01)

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
by: Keming Huang, et al.
Published: (2023-04-01)

Cryo-EM structure of the potassium-chloride cotransporter KCC4 in lipid nanodiscs
by: Michelle S Reid, et al.
Published: (2020-04-01)

Membrane transporters control cerebrospinal fluid formation independently of conventional osmosis to modulate intracranial pressure
by: Eva K. Oernbo, et al.
Published: (2022-08-01)

The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?
by: Ayami Naito, et al.
Published: (2024-01-01)